Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-α

American Journal of Physiology - Cell Physiology

Volumn 286, Issue 4 55-4, 2004, Pages

  Arenas, Ivan A ^a   Xu, Yi ^a   Lopez Jaramillo, Patricio ^b,c   Davidge, Sandra T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Laboratory of Autonomic Physiology and Electrophysiology   (Colombia)

^c UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

Author keywords

Inflammation; Remodeling; Vasoactive mediators

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN ANTAGONIST; CANDESARTAN; GELATINASE A; MESSENGER RNA; NEUTRALIZING ANTIBODY; PENTOXIFYLLINE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; VASOCONSTRICTOR AGENT;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENZYME RELEASE; HUMAN; HUMAN CELL; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UMBILICAL VEIN; VASCULAR DISEASE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASE 2; RECEPTOR, ANGIOTENSIN, TYPE 1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS; VASOCONSTRICTOR AGENTS;

EID: 2142756708     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00398.2003     Document Type: Article

References (30)

1. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, and Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324: 1098-1104, 1991.
2. Bader M, Peters J, Baltatu O, Muller DN, Luft FC, and Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 79: 76-102, 2001.
3. Blake GJ and Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 41: S37-S42, 2003.
4. Branch DR, Shah A, and Guilbert LJ. A specific and reliable bioassay for the detection of femtomolar levels of human and murine tumor necrosis factors. J Immunol Methods 143: 251-261, 1991.
5. Brunner HR. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 87: 3C-9C, 2001.
6. Costanzo A, Moretti F, Burgio VL, Bravi C, Guido F, Levrero M, and Puri PL. Endothelial activation by angiotensin II through NFκB and p38 pathways: involvement of NFκB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 195: 402-410, 2003.
7. Fernandez-Patron C, Radomski MW, and Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85: 906-911, 1999.
8. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, and Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87: 670-676, 2000.
9. Fernandez-Patron C, Zouki C, Whittal R, Chan JS, Davidge ST, and Filep JG. Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]. FASEB J 15: 2230-2240, 2001.
10. Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res 40: 97-105, 1999.
11. Ferreri NR, Zhao Y, Takizawa H, and McGiff JC. Tumor necrosis factor-alpha-angiotensin interactions and regulation of blood pressure. J Hypertens 15: 1481-1484, 1997.
12. Fichtlscherer S, Rossig L, Breuer S, Vasa M, Dimmeler S, and Zeiher AM. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104: 3023-3025, 2001.
13. Funayama H, Ikeda U, Takahashi M, Sakata Y, Kitagawa S, Takahashi Y, Masuyama J, Furukawa Y, Miura Y, Kano S, Matsuda M, and Shimada K. Human monocyte-endothelial cell interaction induces platelet-derived growth factor expression. Cardiovasc Res 37: 216-224, 1998.
14. Han YP, Tuan TL, Wu H, Hughes M, and Garner WL. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci 114: 131-139, 2001.
15. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Luscher TF, Gay S, and Ruschitzka F. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106: 2184-2187, 2002.
16. Jaffe EA, Hoyer LW, and Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 52: 2757-2764, 1973.
17. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, and Imaizumi T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32: 368-372, 1998.
18. Kalra D, Sivasubramanian N, and Mann DL. Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation 105: 2198-2205, 2002.
19. Libby P and Lee RT. Matrix matters. Circulation 102: 1874-1876, 2000.
20. Madge LA and Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol 70: 317-325, 2001.
21. Mantovani A, Sica A, Colotta F, and Dejana E. The role of cytokines as communication signals between leukocytes and endothelial cells. Prog Clin Biol Res 349: 343-353, 1990.
22. Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert LJ, and Davidge ST. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy 20: 185-194, 2001.
23. Papakonstantinou E, Roth M, Kokkas B, Papadopoulos C, and Karaklulakis G. Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. J Cardiovasc Pharmacol 38: 715-728, 2001.
24. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DP, Teepen H, van der Wal AC, and Borst C. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150: 245-253, 2000.
25. Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC, Ferri C, Desideri G, Gulino A, and Santucci A. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 100: 1646-1652, 1999.
26. 1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ Res 91: 1119-1126, 2002.
27. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, and Egido J. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 38: 1382-1387, 2001.
28. Sternlicht MD and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516, 2001.
29. Vita JA and Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 106: 640-642, 2002.
30. Young JL, Libby P, and Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 88: 554-567, 2002.